Our Company
Genetic Immunity has leveraged its immune amplification platform technology to develop the DermaVir Patch,
its lead nanomedicine candidate in Phase II development for HIV/AIDS. Based on the Company's NanoComp nanoparticle
composition platform and its DermaPrep delivery system, the plasmid DNA within DermaVir Patch's NanoComp nanoparticles
is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.
DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies.
Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific T cells.
>> Genetic Immunity in the News...
| 
